Pentwater Capital Management LP Esperion Therapeutics, Inc. Transaction History

Pentwater Capital Management LP

$11.7 Billion
Q1 2025

A detailed history of Pentwater Capital Management LP transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Pentwater Capital Management LP holds 181,290 shares of ESPR stock, worth $324,509. This represents 0.0% of its overall portfolio holdings.

Number of Shares

181,290

Previous 181,290 -0.0%

Holding current value

$324,509

Previous $398,000 34.42%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$1.84 - $3.24 $333,573 - $587,379	181,290 New	181,290 $402,000
Q1 2023 May 15, 2023	BUY	$1.46 - $7.3 $60,097 - $300,489	41,163 Added 29.38%	181,290 $288,000
Q4 2022 Feb 14, 2023	SELL	$5.09 - $8.5 $585,171 - $977,202	-114,965 Reduced 45.07%	140,127 $872,000
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $373,924 - $557,799	-68,610 Reduced 21.2%	255,092 $1.71 Million
Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $163,630 - $228,807	-34,304 Reduced 9.58%	323,702 $2.06 Million
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $15,277 - $25,431	-4,574 Reduced 1.26%	358,006 $1.66 Million
Q4 2021 Feb 11, 2022	BUY	$4.81 - $11.92 $1.74 Million - $4.32 Million	362,580 New	362,580 $1.81 Million
Q3 2021 Nov 15, 2021	SELL	$11.34 - $21.37 $3.28 Million - $6.18 Million	-289,183 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$19.4 - $28.71 $6.18 Million - $9.14 Million	-318,397 Reduced 52.4%	289,183 $6.12 Million
Q1 2021 May 17, 2021	BUY	$25.12 - $36.89 $2.76 Million - $4.06 Million	110,000 Added 22.11%	607,580 $17 Million
Q4 2020 Feb 16, 2021	SELL	$24.2 - $35.76 $40.4 Million - $59.8 Million	-1,671,442 Reduced 77.06%	497,580 $12.9 Million
Q3 2020 Nov 16, 2020	SELL	$31.18 - $52.71 $2.29 Million - $3.87 Million	-73,500 Reduced 3.28%	2,169,022 $80.6 Million
Q2 2020 Aug 14, 2020	SELL	$30.04 - $51.31 $2.12 Million - $3.62 Million	-70,500 Reduced 3.05%	2,242,522 $115 Million
Q1 2020 May 15, 2020	BUY	$27.44 - $73.84 $1.64 Million - $4.41 Million	59,761 Added 2.65%	2,313,022 $72.9 Million
Q4 2019 Feb 14, 2020	SELL	$35.4 - $59.82 $7.97 Million - $13.5 Million	-225,000 Reduced 9.08%	2,253,261 $134 Million
Q3 2019 Nov 14, 2019	BUY	$34.47 - $47.53 $1.47 Million - $2.03 Million	42,761 Added 1.76%	2,478,261 $90.9 Million
Q2 2019 Aug 14, 2019	SELL	$40.1 - $52.33 $1.64 Million - $2.15 Million	-41,000 Reduced 1.66%	2,435,500 $113 Million
Q1 2019 May 15, 2019	SELL	$40.11 - $53.57 $433,188 - $578,556	-10,800 Reduced 0.43%	2,476,500 $99.4 Million
Q4 2018 Feb 14, 2019	BUY	$36.99 - $59.11 $5.02 Million - $8.03 Million	135,800 Added 5.78%	2,487,300 $114 Million
Q3 2018 Nov 14, 2018	SELL	$40.74 - $51.41 $4.58 Million - $5.78 Million	-112,500 Reduced 4.57%	2,351,500 $104 Million
Q2 2018 Aug 14, 2018	BUY	$36.2 - $76.4 $5.56 Million - $11.7 Million	153,500 Added 6.64%	2,464,000 $96.6 Million
Q1 2018 May 15, 2018	BUY	$65.94 - $80.76 $25.1 Million - $30.8 Million	381,269 Added 19.76%	2,310,500 $167 Million
Q4 2017 Feb 07, 2018	SELL	$43.47 - $67.43 $13.6 Million - $21.2 Million	-313,969 Reduced 14.0%	1,929,231 $127 Million
Q3 2017 Nov 14, 2017	BUY	$43.8 - $52.77 $98.3 Million - $118 Million	2,243,200	2,243,200 $112 Million

Others Institutions Holding ESPR

# of Institutions

195

Shares Held

121M

Call Options Held

171K

Put Options Held

679K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $119M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pentwater Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Pentwater Capital Management LP with notifications on news.

Account

Pentwater Capital Management LP Esperion Therapeutics, Inc. Transaction History